|Mr. Kim D. Blickenstaff||Exec. Chairman||588.42k||N/A||1952|
|Mr. John F. Sheridan||Pres, CEO & Director||739.88k||N/A||1955|
|Ms. Leigh A. Vosseller||Exec. VP, CFO & Treasurer||695.16k||N/A||1973|
|Mr. David B. Berger||Exec. VP, Chief Legal & Compliance Officer and Corp. Sec.||737.74k||317.3k||1970|
|Mr. Brian B. Hansen||Exec. VP & Chief Commercial Officer||738.08k||879k||1968|
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 10.